In plain language
In 860 chronic total occlusion percutaneous coronary intervention (PCI) procedures, newer cath lab X-ray systems were associated with lower patient dose-area product after adjusting for fluoroscopy time and body mass index (BMI). Staff dose was not measured.
At a glance
- Type of study
- Original research, Retrospective cohort study
- Who was studied
- Patients
- Size
- n = 860 procedures
- Summary based on
- the abstract
What it found
The X-ray system used had a significant effect on dose-area product (DAP) in chronic total occlusion (CTO) PCI after controlling for fluoroscopy time and BMI.
Key figures: P ≤ 0.001
The most modern X-ray systems produced the lowest radiation doses.
CTO PCI involved long fluoroscopy times and high patient dose overall.
Key figures: mean fluoroscopy time 40.00 ± 19.99 min; mean DAP 11,980 ± 7,947 cGycm2
Limits to keep in mind
Retrospective design with only three operators across three sites, and systems were confounded with hospital site and time period. Only patient DAP was measured; staff dose was not assessed, and the abstract gives no per-system effect sizes.
Related research summaries
- Fluoroscopy-minimization strategy for catheter ablation of Supraventricular Tachycardia by wOmen OPerators: the STOOP Multicentre Registry (2026, Prospective cohort study)
- Two Central Nervous System Tumors in One Catheter Lab: Time to Rethink Radiation Protection (2026, Retrospective cohort study)
- Radiation Awareness for EVAR in Hybrid Operating Room: An Instant Operator Risk Chart (2021, Dosimetry measurement study)
- Utilization of a Radiation Safety Time-Out Reduces Radiation Exposure During Electrophysiology Procedures (2019, Prospective cohort study)
- Completely nonfluoroscopic catheter ablation of left atrial arrhythmias and ventricular tachycardia (2018, Case report or series)
How this summary was made
ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.
Prepared November 3, 2026.